Sarah Gordon-Wild
Directeur/Membre du Conseil chez Leweston School
Fortune : 386 188 $ au 31/05/2024
Postes actifs de Sarah Gordon-Wild
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Corporate Officer/Principal | - | - |
Directeur/Membre du Conseil | - | - | |
Leweston School | Directeur/Membre du Conseil | - | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | - | - |
Larkham Ltd. | Directeur/Membre du Conseil | - | - |
Sgw Research Ltd. | Directeur/Membre du Conseil | - | - |
The Bridport Literary Festival Ltd. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Sarah Gordon-Wild
Anciens postes connus de Sarah Gordon-Wild
Sociétés | Poste | Début | Fin |
---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Directeur/Membre du Conseil | 01/01/2015 | 19/12/2023 |
REDX PHARMA PLC | Directeur/Membre du Conseil | 01/07/2020 | 30/09/2023 |
Independent Dir/Board Member | 01/07/2020 | 30/09/2023 | |
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Directeur Général | 01/01/1998 | 01/01/2003 |
Formation de Sarah Gordon-Wild
Imperial College London | Graduate Degree |
University of Aberdeen | Undergraduate Degree |
Statistiques
Internationale
Royaume-Uni | 12 |
Opérationnelle
Director/Board Member | 8 |
Corporate Officer/Principal | 1 |
Independent Dir/Board Member | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 3 |
Electronic Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Technology |
REDX PHARMA PLC | Health Technology |
Entreprise privées | 7 |
---|---|
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Finance |
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Retail Trade |
Leweston School | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Larkham Ltd. | |
Sgw Research Ltd. | |
The Bridport Literary Festival Ltd. |
- Bourse
- Insiders
- Sarah Gordon-Wild
- Expérience